These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 25202070)

  • 1. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
    Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
    Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
    Larson RA
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
    Galmarini CM
    IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
    Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
    Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.
    Balakrishnan K; Nimmanapalli R; Ravandi F; Keating MJ; Gandhi V
    Blood; 2006 Oct; 108(7):2392-8. PubMed ID: 16778146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
    Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
    Korycka A; Błoński JZ; Robak T
    Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.
    Gandhi V; Balakrishnan K
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S8-12. PubMed ID: 18086347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies.
    Furman RR; Hoelzer D
    Semin Oncol; 2007 Dec; 34(6 Suppl 5):S29-34. PubMed ID: 18086344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
    Robak T; Lech-Maranda E; Korycka A; Robak E
    Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
    Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
    Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.
    Ravandi F; Gandhi V
    Expert Opin Investig Drugs; 2006 Dec; 15(12):1601-13. PubMed ID: 17107284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
    Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
    Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
    Rodriguez CO; Gandhi V
    Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
    Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
    Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.